pdufa.bio
Home › Decisions › PTGX 2026-03-18

PTGX FDA decision — Mar 18, 2026

✓ APPROVED

Protagonist Therapeutics Inc. — ICOTYDE (icotrokinra) · Plaque psoriasis.

Run-up into the decision (T-120 → T+5)

PDUFA 3/18/26$97.23$6410/1/25
Daily close, T-120 (10/1/25) through T+5. Run-up high $97.23 on 3/17/26, low $64 on 10/8/25 (T-120 to T-1). FDA decision 3/18/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-03-18
OutcomeApproved
Drug / candidateICOTYDE (icotrokinra)
CompanyProtagonist Therapeutics Inc.
120-day run-up (T-120→T-1)+47.4%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio